CompanyGraph
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
600671 · SSE · China
hztmyy.comFinancials as of FY2025
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- FinancialsAltman Z-Score 4.13: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
2.56BCNY381.21M · vs all stocks (USD)
Trailing P/E
163.92xRevenue (TTM)
203.85MCNY30.31M · vs all stocks (USD)
Profit Margin
8.02%Beta
0.0130xvs all stocks
52-Week Change
16.94%vs all stocks
Market Capitalization
2.56BCNY381.21M · vs all stocks (USD)
Enterprise Value
2.70BCNY401.08M · vs all stocks (USD)
Trailing P/E
163.92xForward P/E
177.58xPrice to Sales (TTM)
12.73xPrice to Book (MRQ)
35.17xEnterprise to Revenue
13.23xEnterprise to EBITDA
88.23xGross Margin
54.76%Profit Margin
8.02%Operating Margin
13.33%Return on Assets (TTM)
2.16%Return on Equity (TTM)
7.98%Revenue (TTM)
203.85MCNY30.31M · vs all stocks (USD)
Revenue per Share (TTM)
1.67CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-15.10%Gross Profit (TTM)
103.05MCNY15.33M · vs all stocks (USD)
EBITDA (TTM)
21.83MCNY3.25M · vs all stocks (USD)
Net Income (TTM)
16.34MCNY2.43M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-25.10%Operating Cash Flow (TTM)
2.01MCNY299.49K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.08MCNY-6.11M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
23.99MCNYFY2025 · Dec 31, 2025Revenue
211.75MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
110.61MCNYFY2025 · Dec 31, 2025Gross Profit
101.14MCNYFY2025 · Dec 31, 2025Operating Income
17.17MCNY2.55M · vs all stocks (USD)
Pre-tax Income
10.22MCNYFY2025 · Dec 31, 2025Income Tax Expense
3.02MCNYFY2025 · Dec 31, 2025Net Income
7.20MCNYFY2025 · Dec 31, 2025EBIT
17.42MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
45.45MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
25.06MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.82MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
138.60KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
7.20MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1447CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1447CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
121.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
121.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.20MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-10.94MCNYFY2025 · Dec 31, 2025Free Cash Flow
-42.10MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.20MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-50.12MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.22MCNYFY2025 · Dec 31, 2025Capital Expenditures
-31.15MCNYFY2025 · Dec 31, 2025Sale of Investments
3.99KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-31.15MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
162.14MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-144.73MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-6.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.74MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
121.78MSharesUpdated Aug 20, 2026Float Shares
43.92MSharesUpdated Aug 20, 2026% Held by Insiders
55.13%vs all stocks
% Held by Institutions
0.95%vs all stocks
Total Cash (MRQ)
44.80MCNY6.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.3680CNYUpdated Aug 20, 2026Total Debt (MRQ)
198.99MCNY29.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.05xCurrent Ratio (MRQ)
0.8400xBook Value per Share (MRQ)
0.6060CNYUpdated Aug 20, 2026Total Assets
442.03MCNY65.73M · vs all stocks (USD)
Total Current Assets
228.48MCNYFY2025 · Dec 31, 2025Total Liabilities
348.04MCNYFY2025 · Dec 31, 2025Total Non-current Assets
213.55MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
65.62MCNYFY2025 · Dec 31, 2025Total Current Liabilities
282.42MCNYFY2025 · Dec 31, 2025Cash
27.62MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.27MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
31.89MCNYFY2025 · Dec 31, 2025Accounts Receivable
143.84MCNYFY2025 · Dec 31, 2025Inventory
39.18MCNYFY2025 · Dec 31, 2025Accounts Payable
80.90MCNYFY2025 · Dec 31, 2025Short-term Debt
157.60MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.58MCNYFY2025 · Dec 31, 2025Long-term Debt
8.65MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
121.78MCNYFY2025 · Dec 31, 2025Retained Earnings
-238.74MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
93.99MCNY13.98M · vs all stocks (USD)
52-Week Low
15.70CNYUpdated Aug 20, 202652-Week High
23.44CNYUpdated Aug 20, 202652-Week Change
16.94%vs all stocks
Beta
0.0130xvs all stocks
50-Day MA
19.38CNYUpdated Aug 20, 2026200-Day MA
19.17CNYUpdated Aug 20, 2026Avg 10-Day Volume
3.71MSharesUpdated Aug 20, 2026Avg 30-Day Volume
5.43MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.1300CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 2,430,578.401Operating Cash Flow (USD, TTM): 299,492.571
Financial Health
Altman Z-Score 4.13: safe zoneNotable
Altman Z-Score: 4.13
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Coforge Limited
1 interpretationReceivables Heavy and Growing
Zeta Global Holdings Corp.
1 interpretationReceivables Heavy and Growing
Integer Holdings Corporation
1 interpretationReceivables Heavy and Growing